Citations

Showing 10 of 108094 citations.

Addressing Physician Burnout
Williams, Amy , Williams, Amy W.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | January 11, 2018 | Volume: 13 | Issue: 2 | Pages: 325-327

10.2215/cjn.06800617 | PMID 29326308 Get It

Validation of the Modified Surgeon Periorbital Rating of Edema and Ecchymosis (SPREE) Questionnaire: A Prospective Analysis of Facial Plastic and Reconstructive Surgery Procedures
Oliver, Jeremie D. , Menapace, Deanna C., Younes, Ahmed , Recker, Chelsey, Menapace, Deanna, Hamilton, Grant , Oliver, Jeremie D , Friedman, Oren A

Mayo Clinic

Facial Plastic Surgery | January 11, 2018 | Volume: 34 | Issue: 01 | Pages: 095-101

10.1055/s-0037-1615282 | PMID 29325183 Get It

AbstractAlthough periorbital edema and ecchymosis are commonly encountered after facial plastic and reconstructive surgery procedures, there is currently no validated grading scale to qualify these findings. In this study, the modified “Surgeon Periorbital Rating of Edema and Ecchymosis (SPREE)” questionnaire is used as a grading scale for patients undergoing facial plastic surgery procedures. This article aims to validate a uniform grading scale for periorbital edema and ecchymosis using the modified SPREE questionnaire in the postoperative period. This is a prospective study including 82 patients at two different routine postoperative visits (second and seventh postoperative days), wherein the staff and resident physicians, physician assistants (PAs), patients, and any accompanying adults were asked to use the modified SPREE questionnaire to score edema and ecchymosis of each eye of the patient who had undergone a plastic surgery procedure. Interrater and intrarater agreements were then examined. Cohen's kappa coefficient was calculated to measure intrarater and interrater agreement between health care professionals (staff physicians and resident physicians); staff physicians and PAs; and staff physicians, patients, and accompanying adults. Good to excellent agreement was identified between staff physicians and resident physicians as well as between staff physicians and PAs. There was, however, poor agreement between staff physicians, patients, and accompanying adults. In addition, excellent agreement was found for intraobserver reliability during same-day visits. The modified SPREE questionnaire is a validated grading system for use by health care professionals to reliably rate periorbital edema and ecchymosis in the postoperative period. Validation of the modified SPREE questionnaire may improve ubiquity in medical literature reporting and related outcomes reporting in future.
[18F]AV‐1451 clustering of entorhinal and cortical uptake in Alzheimer's disease
Whitwell, Jennifer L. , Graff‐Radford, Jonathan, Tosakulwong, Nirubol , Weigand, Stephen D. , Senjem, Matthew L. , Schwarz, Christopher G. , Spychalla, Anthony J., Drubach, Daniel A., Ertekin‐Taner, Nilüfer , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Schwarz, Christopher G , Jack, Clifford R , Senjem, Matthew L , Graff‐Radford, Jonathan , Machulda, Mary M. , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Annals of Neurology | January 11, 2018 | Volume: 83 | Issue: 2 | Pages: 248-257

10.1002/ana.25142 | PMID 29323751 Get It

ObjectiveTo use a cluster analysis of [18F]AV‐1451 tau‐PET data to determine how subjects with Alzheimer's disease (AD) vary in the relative involvement of the entorhinal cortex and neocortex, and determine whether relative involvement of these two regions can help explain variability in age and clinical phenotype in AD.MethodsWe calculated [18F]AV‐1451 uptake in entorhinal cortex and neocortex in 62 amyloid‐positive AD patients (39 typical and 23 atypical presentation). tau‐PET (positron emission tomography) values were normalized to the cerebellum to create standard uptake value ratios (SUVRs). tau‐PET SUVRs were log‐transformed and clustered blinded to clinical information into three groups using K‐median cluster analysis. Demographics, clinical phenotype, cognitive performance, and apolipoprotein e4 frequency were compared across clusters.ResultsThe cluster analysis identified a cluster with low entorhinal and cortical uptake (ELo/CLo), one with low entorhinal but high cortical uptake (ELo/CHi), and one with high cortical and entorhinal uptake (EHi/CHi). Clinical phenotype differed across clusters, with typical AD most commonly observed in the ELo/CLo and EHi/CHi clusters, and atypical AD most commonly observed in the ELo/CHi cluster. The ELo/CLo cluster had an older age at PET and onset than the other clusters. Apolipoprotein e4 frequency was lower in the ELo/CHi cluster. The EHi/CHi cluster had the worst memory impairment, whereas the ELo/CHi cluster had the worst impairment in nonmemory domains.InterpretationThis study demonstrates considerable variability in [18F]AV‐1451 tau‐PET uptake in AD, but shows that a straightforward clustering based on entorhinal and cortical uptake maps well onto age and clinical presentation in AD. Ann Neurol 2018 Ann Neurol 2018;83:248–257
Survivorship care planning in neuro-oncology
Acquaye, Alvina , Bell, Susan D. , Clarke, Jennifer , Forst, Deborah , Link, Michael J. , Taylor, Jennie , Armstrong, Terri S. , Armstrong, Terri S , Leeper, Heather , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology Practice | January 11, 2018 | Volume: 5 | Issue: 1 | Pages: 3-9

10.1093/nop/npx034 | PMID 31386011 Get It

Abstract Cancer patient survivorship has become a significant topic within oncology care for both adult and pediatric patients. Starting in 2005, the Institute of Medicine recommended the use of survivorship care plans to assist patients transitioning from active treatment to the posttreatment phase of their cancer care, a critical time for many patients. Since 2014 there has been a mandate within the United States for adult cancer patients treated with curative intent to receive survivorship care plans comprised of a treatment summary and a follow-up plan to facilitate a better understanding among patients of what to expect after treatment. In addition to a general oncology survivorship care plan, specific care plans have been created for breast, lung, prostate, and colon cancers, as well as lymphoma. A survivorship care plan specific to adult neuro-oncology has been developed by a multidisciplinary and interprofessional committee, with approval from the Society for Neuro-Oncology Guidelines Committee. It has been published in compendium with this review of survivorship care planning and available as a fillable PDF on the Society of Neuro-Oncology Guidelines Endorsement web page (https://www.soc-neuro-onc.org/SNO/Resources/Survivorship_Care_Plan.aspx). Implementation of this survivorship care plan provides a unique opportunity to begin addressing the range of survivorship issues our neuro-oncology patients navigate from diagnosis to end of life.
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, Vijay , Kumar, Shaji

Mayo Clinic

Leukemia & Lymphoma | January 11, 2018 | Volume: 59 | Issue: 11 | Pages: 2524-2534

10.1080/10428194.2017.1421760 | PMID 29322846 Get It

MicroRNA501‐5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells
Stephanis, Lucia de , Mangolini, Alessandra, Servello, Miriam, Harris, Peter C. , Dell’Atti, Lucio, Aguiari, Gianluca , Harris, Peter C , Dell’Atti, Lucio , Pinton, Paolo

Mayo Clinic

Journal of Cellular Physiology | January 11, 2018 | Volume: 233 | Issue: 9 | Pages: 6911-6924

10.1002/jcp.26473 | PMID 29323708 Get It

Cell proliferation and apoptosis are typical hallmarks of autosomal dominant polycystic kidney disease (ADPKD) and cause the development of kidney cysts that lead to end‐stage renal disease (ESRD). Many factors, impaired by polycystin complex loss of function, may promote these biological processes, including cAMP, mTOR, and EGFR signaling pathways. In addition, microRNAs (miRs) may also regulate the ADPKD related signaling network and their dysregulation contributes to disease progression. However, the role of miRs in ADPKD pathogenesis has not been fully understood, but also the function of p53 is quite obscure, especially its regulatory contribution on cell proliferation and apoptosis. Here, we describe for the first time that miR501‐5p, upregulated in ADPKD cells and tissues, induces the activation of mTOR kinase by PTEN and TSC1 gene repression. The increased activity of mTOR kinase enhances the expression of E3 ubiquitin ligase MDM2 that in turn promotes p53 ubiquitination, leading to its degradation by proteasome machinery in a network involving p70S6K. Moreover, the overexpression of miR501‐5p stimulates cell proliferation in kidney cells by the inhibition of p53 function in a mechanism driven by mTOR signaling. In fact, the downregulation of this miR as well as the pharmacological treatment with proteasome and mTOR inhibitors in ADPKD cells reduces cell growth by the activation of apoptosis. Consequently, the stimulation of cell death in ADPKD cells may occur through the inhibition of mTOR/MDM2 signaling and the restoring of p53 function. The data presented here confirm that the impaired mTOR signaling plays an important role in ADPKD.
Chronic traumatic encephalopathy in an epilepsy surgery cohort
Jones, Amy L., Blessing, Melissa M. , Parisi, Joseph E. , Cascino, Gregory D. , Britton, Jeffrey W.

Mayo Clinic

Neurology | January 11, 2018 | Volume: 90 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000004927 | PMID 29321231 Get It

Nasogastric tube and outcomes of Clostridium difficile infection: A systematic review and meta‐analysis
Wijarnpreecha, Karn , Sornprom, Suthanya, Phatharacharukul, Parkpoom , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn

Mayo Clinic

Journal of Evidence-Based Medicine | January 11, 2018 | Volume: 11 | Issue: 1 | Pages: 40-45

10.1111/jebm.12288 | PMID 29322624 Get It

AbstractAimsClostridium difficile infection (CDI) is a major concern for public health worldwide. Interestingly, the risk of poor clinical outcomes of CDI in patients with nasogastric tube (NGT) insertion is still controversial. The aim of this study was to assess the outcomes of CDI in patients with NGT insertion.MethodsA literature search was performed using MEDLINE, EMBASE, and The Cochrane Database of Systematic Reviews from inception through November 2017. Studies that reported relative risks, odds ratios, or hazard ratios comparing the clinical outcome of CDI in patients with NGT versus those who did not were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random‐effect, generic inverse variance method.ResultsEight observational studies were included in our analysis to assess the association between NGT insertion and risk of poor outcome of CDI. The pooled RR of severe or complicated clinical outcomes of CDI in patients with NGT insertion was 1.81 (95% CI: 1.17 to 2.81).ConclusionsThis study demonstrated a statistically significant association between NGT insertion and risk of poor outcomes of CDI. This finding may impact clinical management and primary prevention of CDI. Avoidance of unnecessary NGT uses would improve the clinical outcomes of CDI.
Feasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction
Keller, Cesar A., Gonwa, Thomas A., Hodge, David O. , Hei, Derek J. , Centanni, John M., Keller, Cesar Ariel , Gonwa, Thomas Arthur, Hodge, David Orel, Zubair, Abba Chedi, Zubair, Abba C.

Mayo Clinic

Stem Cells Translational Medicine | January 11, 2018 | Volume: 7 | Issue: 2 | Pages: 161-167

10.1002/sctm.17-0198 | PMID 29322685 Get It

Abstract Feasibility, tolerance, and safety of intravenous infusions of allogeneic mesenchymal stem cell (MSC) therapy in lung transplant recipients with bronchiolitis obliterans syndrome (BOS) are not well established. MSCs were manufactured, cryopreserved, transported to our facility, thawed, and infused into nine recipients with moderate BOS (average drop in forced expiratory volume in 1 second was 56.8% ± 3.2% from post-transplant peak) who were refractory to standard therapy and not candidates for retransplant. Cells were viable and sterile prior to infusion. Patients received a single infusion of either 1 (n = 3), 2 (n = 3), or 4 (n = 3) million MSCs per kg. Patients were medically evaluated before; during; and at 24 hours, 1 week, and 1 month after infusion for evidence of infusion-related adverse events and tolerance of therapy. Vital signs, pulmonary function test results, Borg Dyspnea Index, and routine laboratory data were recorded. Vital signs and O2 saturation did not significantly change during or up to 2 hours after MSC infusion. There were no significant changes in gas exchange variables, pulmonary function test results, or laboratory values at 1, 7, and 30 days postinfusion compared with preinfusion values. Infusion of MSCs in patients with BOS was feasible, safe, and well tolerated and did not produce any significant adverse changes in clinical, functional, or laboratory variables during or up to 30 days after infusion. Manufacturing, transport, and administration of intravenous, allogeneic bone marrow-derived MSCs in doses from 1 to 4 million MSCs per kg is safe in lung transplant recipients with BOS.
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
Brook, Jill, Myers, Trisha L, Goodman, Brent P., Goodman, Brent, Weinstock, Leonard B.

Mayo Clinic

BMJ Case Reports | January 11, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2017-221405

10.1136/bcr-2017-221405 | PMID 29326369 Get It

A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role.